Hagen Kennecke
@hkennecke
GI and NET Oncologist, @OHSU Knight Cancer Institute, Chief & Med Dir CHO and Knight-Legacy Collaborative, Dad, cycling & ski enthusiast!
ID: 2378288102
08-03-2014 06:54:27
1,1K Tweet
1,1K Followers
445 Following
Caught up with so many of my Canadian 🇨🇦 besties at #ASCO24 Sharlene Gill, MD, MPH, MBA, FASCO Jonathan Loree !
EA#2174 NCI CTEP Clinical Research: A phase II/III study of perioperative nivo/ipi in locally adv esophageal and GEJ adenoCA. Though NS benefit for pCR (21% vs. 24.8%). 👏Dr. Jennifer Eads Penn Medicine - Abramson Cancer Center for discussing the IMP of #cancerresearch in #rarecancers. ECOG-ACRIN Cancer Research Group #ASCO24 @asco
#ASCO24: NRG 0848 final results show no benefit of added post-op CRT to historic chemo in R1 PDAC but possible benefit in pN0. Future trials of post-op CRT with modern adjuvant chemo are planned. Dr. Nina Niu Sanford NRG Oncology
#ASCO24: Mature CHECKMATE 90W IPI3/NIVO1 in unresectable #HCC vs TKI had significantly improved OS and RR of 36%. Another 1st line option. 29% use of high dose steroids for immune AEs. OncoAlert Dr. Cathy Eng Laura Goff Syed A. Ahmad
Updated DYNAMIC results support the routine use of #ctDNA to guide adjuvant chemo decisions in stage II #coloncancer ; including pT4. Jonathan Loree Pashtoon Kasi MD, MS Mark Whiteford Manju George MVSc PhD Rectal Cancer Survivor Fight Colorectal Cancer
NICHE-2 published in NEJM —what an elegant work from super star Myriam Chalabi and senior John Haanen ! Study presented #ESMO22 and started the hashtag #ChalabiPlot => near 100% pathologic response in dMMR colon cancer! OncoAlert
Accrual has begun for NEO-RT trial! Appreciate the support of Jason Zell Joe Carmichael MD UC Irvine Surgery UCI Health , among the first to enroll patients! Keep it up!
First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated #coloncancer, OS HR=0.4. Patients are asking: do we recommend COX-2 for the 20% with mut PIK3CA❓ Need to do NGS for all stage III CRC. Journal of Clinical Oncology
As presented at #ASCO23 - I offer PRODIGE 23 strategy with induction FOLFIRINOX to all patients with high-risk #rectalcancer. Or JANUS trial, whenever possible. Josh Smith, MD, PhD, FACS Mark Whiteford Thomas George MD, FACP, FASCO William A Hall, MD Arvind Dasari, MD, MS
SWOG Cancer Research Network AIMS #rectalcancer trial results: The diet modification intervention significantly reduced LARS - mean scores ⬇️ from Major to Minor. This could help patients with LARS. Jason Zell COLONTOWN Fight Colorectal Cancer search.app/iXob3FRYasPZMK…
Summertime is fire time in the Columbia River Gorge. Stay fire 🔥 safe! Not quite like the romantic commuter pics posted by Thor Halfdanarson, but still beautiful here!
Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum AnnalsSurgOncology link.springer.com/article/10.124…